New kidney research is expanding the semaglutide conversation beyond weight loss. Explore the FLOW and REMODEL findings, their limits, and what to track with Peptimize.
Semaglutide is usually discussed in terms of appetite, blood sugar and weight. Kidney health is now becoming a more visible part of the conversation, and the latest research asks a different question: what might this treatment be doing inside the kidney?
A study published in Nature Medicine on October 1, 2026 brings that question back into focus. It follows earlier clinical evidence that semaglutide can improve kidney outcomes in a defined group of patients. The two kinds of research serve different purposes, and understanding that difference makes the headlines much more useful.
The key message: evidence of kidney benefit deserves attention, but it should not become a promise that every person taking a GLP-1 is protected from kidney disease.
For someone following treatment week by week, the scale provides an easy number to watch. Kidney health is less visible. Early chronic kidney disease often causes no symptoms, so feeling well does not replace testing.
Clinicians commonly use a blood-based estimate of filtration, called eGFR, and a urine test for albumin. The urine albumin-to-creatinine ratio, or UACR, helps assess protein leakage. These measurements answer different questions and are interpreted together, over time. People with diabetes should be checked for kidney disease annually; the schedule for other risk groups should be discussed with a healthcare professional.
That creates an important practical distinction: your medication and symptom history can support a review, while laboratory results assess kidney health. One cannot substitute for the other.
The FLOW trial enrolled 3,533 people with type 2 diabetes and chronic kidney disease. Participants received weekly injected semaglutide 1 mg or placebo alongside standard care, with median follow-up of 3.4 years.
Semaglutide lowered the hazard of the primary composite outcome by 24%. That outcome combined kidney failure, a decline of at least 50% in eGFR, and death from kidney or cardiovascular causes. There were 331 first events in the semaglutide group and 410 in the placebo group.
This was a relative reduction in a combined outcome, not a 24-percentage-point improvement in kidney function. The trial also found a slower average decline in eGFR. These are meaningful findings in the population studied, but they do not demonstrate that established kidney damage has been reversed.
FLOW tested a particular formulation and dose in people with both diabetes and CKD. It was not a trial of every GLP-1 medicine, every semaglutide product, or otherwise healthy people seeking weight loss. It was funded by Novo Nordisk.
REMODEL was a smaller, 52-week randomized study of 106 participants with type 2 diabetes and CKD. It compared weekly injected semaglutide 1 mg with placebo and investigated possible mechanisms using kidney imaging and, in smaller subgroups, biopsies and molecular analyses.
Its three main MRI outcomes (measures of oxygenation, overall perfusion and tissue inflammation) did not differ significantly between groups. That finding matters and should remain part of any account of the study.
Some secondary measures suggested lower vascular resistance and less progression of fibrosis-related imaging changes. Tissue analyses also identified changes involving glomerular endothelial cells, which line blood vessels in the kidney’s filtering structures.
These findings offer possible explanations for kidney protection. They do not establish a single proven mechanism or provide another large clinical-outcomes result like FLOW. The small tissue subgroups and multiple analyses warrant caution. A study that explores how a treatment may work is answering a different question from a trial measuring kidney failure or death.
No. A research result is not an individual treatment recommendation. The US Ozempic label includes reduction of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and CKD. That indication has a defined population; it does not automatically apply to other formulations, other medicines or people without those conditions.
For a reader, the useful next step is to ask how the evidence fits their diagnosis and current care. Starting, switching or increasing medication solely because of a kidney headline skips that assessment.
Questions worth taking to your clinician include:
A medicine can improve long-term outcomes in an appropriate population while still requiring careful attention to side effects. Ozempic’s prescribing information warns about acute kidney injury related to volume depletion, often in the setting of gastrointestinal symptoms such as nausea, vomiting or diarrhea. It recommends renal-function monitoring when adverse reactions could cause volume depletion.
Persistent vomiting, inability to keep fluids down, markedly reduced urination or significant dizziness deserve prompt medical assessment. A favourable research headline is not a reason to dismiss those symptoms. People with prescribed fluid restrictions should follow their clinician’s plan rather than adopt a universal water target.
Peptimize helps organize the everyday details that are easy to forget between appointments: doses, medication history, weight, appetite and side effects. Used consistently, those records can give a clinician a clearer timeline of your experience.
It is a tracking tool. It does not measure kidney function, diagnose dehydration, interpret laboratory tests or recommend dose changes.
Instead of saying, “I felt unwell sometime after my injection,” you might bring: “These are my dose dates. I recorded vomiting on these two days, and this is when it became difficult to drink. Here are my recent laboratory reports.”
That summary does not diagnose the cause. It gives your healthcare team a more reliable sequence to assess. The value is in reducing uncertainty about what happened and when.
The semaglutide conversation is expanding beyond weight loss. FLOW provides evidence about clinical kidney outcomes in people with type 2 diabetes and CKD; REMODEL offers clues about possible underlying biology while leaving its main imaging outcomes unchanged.
For readers, the most useful response is to connect the evidence with their own clinical review: understand the population studied, ask about appropriate testing, and keep treatment and side-effect records organized. Peptimize can support that last step while kidney assessment remains with your healthcare team.
Educational information only. This article does not provide a diagnosis or an individual treatment plan. Evidence reviewed October 4, 2026.
Educational content only. Nothing here is medical advice, a diagnosis, or a dosing or titration recommendation. Decisions about any medication belong with you and your prescriber.
Wondering if your GLP-1 is working? Discover 8 ways to track GLP-1 progress beyond weight, including appetite, side effects, measurements, medication history, and non-scale victories with Peptimize.
· Peptimize Editorial
Taking Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo or another GLP-1 medication? Learn how to track side effects, injections or daily medication, doses and weight changes, and use Peptimize to identify patterns in your GLP-1 journey over time.
· Peptimize Editorial
Can semaglutide improve knee osteoarthritis pain? Explore the STEP 9 evidence, its limits, and how Peptimize can help organize your medication and weight history.
· Peptimize Editorial
What the 2026 survodutide trials reveal about weight loss and liver fat—and why imaging changes, MASH improvement and fibrosis are different outcomes.
· Peptimize Editorial